25.10.2017

1

2017 nine-month & third-quarter salesWebcast presentation for investors, analysts & media

Basel, 26 October 2017

DisclaimerThis presentation contains certain forward-looking statements that reflect the current views ofmanagement. Such statements are subject to known and unknown risks, uncertainties and otherfactors that may cause actual results, performance or achievements of the Straumann Group todiffer materially from those expressed or implied in this presentation. The Group is providing theinformation in this presentation as of this date and does not undertake any obligation to updateany statements contained in it as a result of new information, future events or otherwise.

The availability and indications/claims of the products illustrated and mentioned in thispresentation may vary according to country.

2

25.10.2017

2

9-months highlights Marco Gadola, CEO

1 Organic growth – i.e. excluding the effects of currency fluctuations and acquired/divested business activities2 Outlook expectations barring unforeseen events/circumstances

4

REVENUE GROWTH TOP PERFORMER BUSINESS DRIVERS

+15% organic1 North America Total solutionsQ3: +16% organic; +21% in CHF9M: +15% organic; +19% in CHF

…generates >30% of Group’s 9M growth;APAC remains fastest-growing region (+24%)

Implants contribute two thirds of 9M growth: BLT and Neodent CM drive premium and non-premium businesses respectively.

EXPANSION PRODUCTS OUTLOOK

New subsidiaries Regulatory approvals RaisedIran opened; preparations for subsidiaries in Turkey & S. Africa underway. Acquisitions of ClearCorrect & Dental Wings completed.

…for key Straumann products (including BLT) in China, Russia and India.Neodent launches new GM implant system.

…for full-year organic revenue growth: 13-15%2

Growth throughout and beyond our space

25.10.2017

3

5

Momentum sustained in Q3 with accelerations in APAC and LATAM

North America28% of Group

17.0 17.2

Q3 9MLATAM

11% of Group

APAC17% of Group

15.9 14.8

Q3 9M

Straumann Group

9.9 10.0

Q3 9M

EMEA 44% of Group

18.915.7

Q3 9M

Growth year-on-year (in %)

27.924.2

Q3 9M

Consistently outperforming the marketOrganic revenue growth since 2012

6

-1.0%

1.2%

6.4%

9.1%

13.1%14.8%

2012 2013 2014 2015 2016 9M 2017

Average7.2%

market growth (incl. Straumann Group)

Double-digit growth over the first 9 months supported across all segments

>3x

++Biomaterials

++Implants

++Restorative

25.10.2017

4

Business and regional reviewPeter Hackel, CFO

8

Further expansion across all regions

12.227.0

32.4

31.9

16.76.0

M&A effect

697.8675.1

Revenues 9M 2016

FX effect

14.8%organic

18.7%CHF

Revenues 9M 2017

801.3

LATAMAPACNorth America

EMEARevenues 9M 2016

@ FX 2017

Revenue development (CHFm, rounded)

Change in organic growth

17.2% 15.7%10.0% 24.2% 31%

31%

26%

12% LATAM

APAC

NorthAmerica

EMEA

Regional share oforganic growth

25.10.2017

5

EMEA performed consistently throughout the first 9-months

Germany was the main contributor, with Iberia, France, Belgium and the UK delivering the strongest increases

Dynamic growth in Russia

Double-digit growth in both the premium and non-premium implant businesses

Higher levels of sales generated from newly acquired customers

Many new customers attracted by Straumann’s novel 2.9mm BLT implant

9

EMEA and North America maintain paceRevenue change (organic)

56%

9.9% 9.9% 10.1% 8.0% 7.7%

11.1%

Q3Q2Q1 2017Q4Q3Q2

North America17.0%

17.2% 17.2%

16.0%

17.3% 16.9%

Q3Q2Q1 2017Q4Q3Q2

EMEA

44% of Group

28% of Group

18.9%

12.8%15.3%15.0%

12.7%

17.2%

Q3Q2Q1 2017Q4Q3Q2

China continues to be main powerhouse; Anthogyr adds to growth

Double-digit increases in Australia, China, South Korea, and Japan

Japan posts strongest quarter this year

Straumann and Neodent gain new customers in weak Brazilian market

Successful launch of Neodent GM Dynamic growth in Mexico; earthquake

disruption not evident in Q3 New subsidiaries in Argentina, Colombia,

and Chile complete build-up phase

10

Asia Pacific and Latin America on fast trackRevenue change (organic)

56%

Latin America

APAC 27.9%

19.4%

25.7%20.5%

17.0%20.2%

Q3Q2Q1 2017Q4Q3Q2

17% of Group

11% of Group

25.10.2017

6

Facility 2017 2018 2019 Output increase1

Villeret (CH) +70%

Andover (US) +60%

Curitiba (BR) +35%

New production building (brownfield)

Capacity expansion to meet growing demand

1 Expected capacity increase from H1 2017 – Q4 201911

New production area in Curitiba Impression of new production building in Villeret

+50% space

New building/modification

Additional machine capacity or working hours

Strategic progress Marco Gadola, CEO

25.10.2017

7

Strategic priorities of the Straumann Group

13

Expand scope to become a Total Solution Provider for esthetic dentistry

Target unexploited growth markets & segments

Drive our high performance STMN Group culture and organization

2'217 2'387

3'4713'797

4'290

2013 2014 2015 2016 9M 2017

Number of employees Medentika & Equinox Dental Wings & ClearCorrect

CH (incl. HQ)20%

Rest of EMEA26%

LATAM25%

NAM19%

APAC10%

Geographical expansion reflected in an increasingly diverse teamEmployees by region (in % of total1)

14 1 Incl. Dental Wings and ClearCorrect, which were consolidated as of 01.10.2017

Headcount development (pro forma1)

4’779

+982

25.10.2017

8

New subsidiaries in Iran, Turkey & South Africa –direct access to large growth marketsIran

Distribution taken over Broader presence; multi-brand strategy Straumann products available in Iran since 2007

Turkey Preparations to establish subsidiary in coming months Intention to incorporate current distributor & team

South Africa Straumann ranks among top 3 premium companies Preparations to open subsidiary, incorporating former distributor & team Cape Town subsidiary to act as regional hub

15

62(500 000)

Implants per 10 000 people

(implant market total)

75(600 000)

13(60 000)

Chinese ‘fire-cracker’ Key regulatory approvals obtained; launches underway for:

Straumann® BLT implants Roxolid® SLActive® for practically all Straumann implants Straumann® Pro Arch edentulous solutions Straumann® Smart enablement & education program Anthogyr Axiom ® PX implants

Launch activities include 3-day Innovation Summit in Shanghai with parallel congresses in Beijing, Guangzhou & Chengdu; large number of participants expected (1600 onsite and 13 000 online yesterday).

New CADCAM milling center in Shenzhen operational in Q2 2018

16

AnthogyrAxiom® PX

Straumann BLT

25.10.2017

9

Other significant regulatory approvals and launches Russia

Straumann® Bone Level Taperedimplant approved

India All Straumann® Soft Tissue Level

& Bone Level implants approved

Major launch event in Mumbai early December

Group now offers a comprehensive range of premium & attractively-priced implant options under the Straumann & Equinox brands.

17

Neodent launches innovative Grand Morse implant system in Brazil

Complete new implant system for all clinical needs, developed from the inside out, starting with the prosthetic interface

Fully tapered design with cutting threads

Comprehensive prosthetic range, including angulated rounded abutments for full-arch restorations, ti-bases and ‘ProPeek’ temporary abutments

1-year clinical evidence: 100% survival of 277 implants in 57 patients1

200 new customers attracted in first month

Roll-out in other regions beginning mid 2018

Grand Morse is expected to become the preferred choice of Neodent customers and to supersede the Cone Morse in the next two years.

181 Data on file

25.10.2017

10

EAO in Madrid

New products despite big launch program at IDS

Straumann P-Series 3D printers enter market Dental Wings’ powder-free intraoral scanner handpiece Straumann® Surgical Motor Pro

Clinical endorsements for Straumann solutions at scientific symposium, focusing on patient-centric protocols, edentulous solutions with Pro Archand Novaloc, and immediacy with BLT

19

Exciting new data on SLActive® implant surface

Discovery of distinct nanostructures on the SLActive®

surface1,2 proves its topography differs from that of SLA®.

Presence of nanostructures

increases surface area by 50%3

enhances (together with surface wettability) • fibrin network formation• cell adhesion• bone-cell mineralization• osseointegration2,4,5

20

Roxolid® SLA® Roxolid® SLActive®

1Kopf BS et al. 2015. The role of nanostructures and hydrophilicity in osseointegration: In-vitro protein-adsorption and blood-interaction studies. J Biomed Mater Res Part A2015:103A:2661–2672. 2Wennerberg A et al. Nanostructures and hydrophilicity influence osseointegration – A biomechanical study in the rabbit tibia. Clin. Oral Impl. Res. 25, 2014, 1041–1050 3Straumann: data on file 4Müller E et al. The interplay of surface chemistry and (nano-)topography defines the osseointegrative potential of Roxolid® dental implant surfaces. eCM Meeting Abstracts 2017, Collection 3; SSB+RM (page 31). 5EMPA (2017) Report additional experiments: Impact of RXD SLA, RXD SLAnano, RXD SLActive, and RXD pmod SLA surfaces on protein adsorption, blood coagulation, and osteogenic differentiation of HBCs. Final report: Impact of RXD SLA, RXD SLAnano, RXD SLActive, and RXD pmod SLA surfaces on protein adsorption, blood coagulation, and osteogenic differentiation of HBCs. EMPA, Swiss Federal Laboratories for Materials Science and Technology (data on file).

Fibr

in n

etw

ork

Adhe

rent

cel

ls

Roxolid SLA®Roxolid SLA®

with nanostructuresRoxolid SLActive®

with nanostructures

25.10.2017

11

Strategic priorities of the Straumann Group

21

Expand scope to become a Total Solution Provider for esthetic dentistry

Target unexploited growth markets & segments

Drive our high performance STMN Group culture and organization

Dental Wings, ClearCorrect & Rapid Shape transactionsclosed

Footnote22

100% 100% 35%Ownership 38%

25.10.2017

12

The orthodontic workflow complements our digital solutions for esthetic dentistry

23

Prostheticworkflow

Orthodonticworkflow

Data capturing

Case designTreatment design

Production

Model production

Alignerproduction

restorations

Doctorapproval

Doctorapproval

implant -borneTooth-borne

Outlook 2017

25.10.2017

13

1 Market growth assessment incl. Straumann Group 2 excl. currency and acquisition effects (ClearCorrect, Dental Wings, Medentika, and Equinox).25

Outlook for 2017Barring unforeseen circumstances

Market growth

Our revenuegrowth

Profitability

We expect the global implant market to grow at approx. 3-4%1 in 2017

Further improvements in the underyling2 operating profit margin despite further investments in

strategic growth initiatives

Confident that we can continue to outperform by achieving organic2 revenue growth of 13-15%

Questions & answers &

25.10.2017

14

27

2017 Event Location

26 October Q3/9M revenue publication Webcast

28 October Investor meetings Paris (F)

31 October Investor meetings Geneva (CH)

16 November Vontobel Healthcare Tour Basel (CH)

17 November Credit Suisse Mid-cap conference Zurich (CH)

23 November HSBC Equities conference Frankfurt (D)

07 December Berenberg Equities conference Pennyhill (UK)

2018 Event Location

15 February Full-year 2017 results conference Straumann Group Headquarters, Basel

04 April AGM 2018 Messe Basel

Calendar of upcoming events

28

Growth strategy pays off

1 In March 2015 Straumann acquired the remaining 51% stake of Neodent (Brazil) which added 930 employees to the Group. In 2017, the incorporation of Equinox in India and Medentika in Germany added 160 employees. Note: 5-year average = 2013 – 9M 2017

in CHF million 2012 2013 2014 2015 2016 9M 2017 5-year averageRevenue 686.3 679.9 710.3 798.6 917.5 801.3

Organic revenue growth in % -1.0 1.2 6.4 9.1 13.1 14.8 8.9Acquisiton / Divesture effect in % -0.6 -0.8 0.0 9.5 0.8 2.9 2.5Change in l.c.% -1.6 0.4 6.4 18.6 13.9 17.7 11.4FX effect in % 0.5 -1.3 -1.9 -6.1 1.0 1.0 -1.5Growth in CHF % -1.1 -0.9 4.5 12.4 14.9 18.7 9.9

2012 2013 2014 2015 2016 H1 2017 CAGR 2012-16Gross profit b. exceptionals 534.4 535.9 558.7 628.0 718.5 420.0 7.7Underlying margin 77.9% 78.8% 78.7% 78.6% 78.3% 77.2%EBIT b. exceptionals 102.1 123.8 148.3 185.7 227.2 139.8 22.1Underlying margin 14.9% 18.2% 20.9% 23.3% 24.8% 25.7%Underlying net profit1 72.7 107.9 130.9 144.7 186.8 117.2 26.6Underlying margin 10.6% 15.9% 18.4% 18.1% 20.4% 21.6%Earnings per share (adjusted) 4.71 6.98 8.42 9.19 11.94 7.57 26.2

2012 2013 2014 2015 2016 H1 2017 CAGR 2012-16Operating cash flow 114.6 151.5 146.2 185.6 184.7 77.5 12.7Capital expenditure (19.4) (12.6) (18.8) (35.2) (46.7) (32.8)as % of revenue -2.8% -1.9% -2.6% -4.4% -5.1% -4.1%Free cash flow 95.2 139.2 128.4 151.1 138.7 45.2 9.9

Number of employees (year-end)1 2'517 2'217 2'387 3'471 3'797 4'227 10.8

25.10.2017

15

60

80

100

120

2014 2015 2016 2017

Development of Straumann’s main exchange rates since 2014

USDCHF EURCHF JPYCHF BRLCHF

CHF36%

EUR19%

USD/CAD/AUD23%

JPY4%

BRL9%

Other9%

CHF8%

EUR31%

USD/CAD/AUD30%

JPY7%

BRL10%

Other15%

Straumann’s currency exposure

1 These distribution charts represent the total net revenues and the total COGS, as well as OPEX in the various currencies. All numbers are rounded and based on FY 2016 figures.

Cost breakdown FY20161

Revenue breakdown FY20161Average exchange rates (rounded) FX sensitivity

(+/- 10%) on full-year...

9M 2016 9M 2017 Latest trend Revenue EBIT

1 EURCHF 1.09 1.10 +/- 29m +/- 18m

1 USDCHF 0.98 0.98 +/- 23m +/- 11m

100 BRLCHF 27.72 30.89 +/- 9m +/- 3m

100 JPYCHF 0.90 0.88 +/- 6m +/- 4m

29

Thank youinvestor.relations@straumann.com